Utilizing IgG Autoantibodies As Biomarkers In IgA Nephropathy
利用 IgG 自身抗体作为 IgA 肾病的生物标志物
基本信息
- 批准号:10608214
- 负责人:
- 金额:$ 61.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAgeAgreementAlabamaAncillary StudyAntigen-Antibody ComplexAsian populationAutoantibodiesAutoantigensAutoimmune DiseasesAutomobile DrivingAwarenessBindingBiological AssayBiological MarkersCaucasiansCertificationCharacteristicsChronic Kidney FailureClinicClinicalClinical Laboratory Improvement AmendmentsClinical TrialsCollaborationsDataDepositionDetectionDevelopmentDiseaseDrug IndustryEnzyme-Linked Immunosorbent AssayEvaluationFundingGalactoseGenderGlomerular Filtration RateGlomerulonephritisGoalsIGA GlomerulonephritisIgA1IgG autoantibodiesInjury to KidneyInstructionIntellectual PropertyKidneyKidney DiseasesKidney FailureLaboratoriesLeadLicensingMeasurementMedical centerModelingMonitorNephrologyNew YorkOutcomePathogenesisPathologicPatientsPerformancePersonsPharmacologic SubstancePhasePolysaccharidesPreparationPrintingProceduresProcessProspective StudiesProteinuriaProtocols documentationPublicationsPublishingQualifyingReagentRenal glomerular diseaseReproducibilityResearchResearch ContractsSamplingSensitivity and SpecificitySeriesSerumSiteSourceSpecimenStandardizationTestingTimeTrainingUnited States National Institutes of HealthUniversitiesValidationbiobankcohortcommercializationcostdetection assaydisease diagnosticfield studyobservational cohort studyoutcome predictionpilot lot productionpre-clinicalprognosticationspecific biomarkerstooltreatment responsevalidation studies
项目摘要
Abstract
IgA nephropathy (IgAN) is the most common primary glomerulonephritis and an important cause of kidney
failure. It is a mesangioproliferative glomerular disease defined by characteristic IgA1 mesangial deposits.
These mesangial deposits likely originate from circulating immune complexes that contain IgA1 with Galactose
(Gal)-deficient O-glycans (Gd-IgA1) that are bound by IgG autoantibodies. The pathogenesis model describing
IgAN as an autoimmune disease was based on the discovery of IgG autoantibodies that bind Gd-IgA1 in the
laboratory of Dr. Jan Novak at the University of Alabama at Birmingham (UAB). As part of these studies, Dr.
Novak's laboratory developed assays for the detection and quantitative assessment of both Gd-IgA1 and IgG
autoantibodies. The use of these assays for analysis of serum samples from several cohorts of IgAN patients
has been published; both the Gd-IgA1 assay and the IgG autoantibody (IgG-AA) assay have potential as
markers for preclinical detection of IgAN, prediction of outcome, and monitoring the response to therapy. The
established pathogenesis model of IgAN enabled pharmaceutical industry to start developing and testing
treatment for the disease. However, only secondary markers (e.g., proteinuria and estimated glomerular
filtration rate [eGFR]) are currently used as the endpoints, adding to the time and cost of clinical trials. Thus,
clinical-grade tests that assess primary causative markers are urgently needed. To address this requisite, we
have licensed the intellectual property from UAB that surrounds the IgAN assays developed in Dr. Novak's
laboratory. In Phase I, we transferred the IgG-AA assay to a contract research organization laboratory setting
to perform standardization of the protocol, fully characterize the components of the assay, and perform a
detailed qualification study on its performance as an initial step in the commercialization process. In Phase II,
we will complete the development of the IgAN IgG-AA test, including development of serum controls, reagent
sourcing, large-scale printing of ELISA plates, and standardized assay instructions for use by partner and/or
Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories. We will perform a series of internal
and external validation studies with key opinion leaders and other accessible bio-repositories. By the end of
Phase II, we will be ready to introduce our IgAN IgG-AA test into the clinic through CLIA lab partnerships.
摘要
伊加肾病(IgAN)是最常见的原发性肾小球肾炎,是肾脏损害的重要原因,
失败它是一种系膜增生性肾小球疾病,由特征性IgA 1系膜沉积物定义。
这些系膜沉积物可能来源于含有半乳糖的IgA 1的循环免疫复合物
由IgG自身抗体结合的(Gal)缺陷型O-聚糖(Gd-IgA 1)。发病机制模型描述
IgAN作为一种自身免疫性疾病是基于发现与Gd-IgA 1结合的IgG自身抗体。
在伯明翰的亚拉巴马大学(UAB)的Jan Novak博士的实验室。作为这些研究的一部分,博士。
Novak的实验室开发了用于检测和定量评估Gd-IgA 1和IgG的检测方法
自身抗体使用这些测定法分析来自几个IgAN患者队列的血清样品,
已发表; Gd-IgA 1测定和IgG自身抗体(IgG-AA)测定均具有作为
用于IgAN临床前检测、预测结果和监测对治疗的反应的标志物。的
IgAN发病机制模型的建立使制药业开始开发和测试
治疗疾病。然而,只有次要标记(例如,蛋白尿和估计肾小球
滤过率[eGFR])目前被用作终点,增加了临床试验的时间和成本。因此,在本发明中,
迫切需要评估主要致病标志物的临床级测试。为了满足这一要求,我们
已经从UAB获得了围绕诺瓦克博士开发的IgAN测定的知识产权。
实验室在第一阶段,我们将IgG-AA检测转移到合同研究组织实验室设置
执行方案标准化,充分表征测定组分,并执行
作为商业化进程的第一步,对其性能进行详细的鉴定研究。在第二阶段,
我们将完成IgAN IgG-AA检测的开发,包括血清对照品、试剂盒的开发,
采购、大规模印刷ELISA平板和供合作伙伴使用的标准化检测说明书,和/或
临床实验室改进修正案(CLIA)-认证实验室。我们将进行一系列的内部
与关键意见领袖和其他可访问的生物储存库进行外部验证研究。年底前
第二阶段,我们将准备通过CLIA实验室合作伙伴关系将IgAN IgG-AA测试引入临床。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRUCE A JULIAN其他文献
BRUCE A JULIAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRUCE A JULIAN', 18)}}的其他基金
Utilizing IgG Autoantibodies As Biomarkers In IgA Nephropathy
利用 IgG 自身抗体作为 IgA 肾病的生物标志物
- 批准号:
10484616 - 财政年份:2020
- 资助金额:
$ 61.63万 - 项目类别:
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
APOL1 长期肾移植结果网络 (APOLLO) 临床中心
- 批准号:
9768568 - 财政年份:2017
- 资助金额:
$ 61.63万 - 项目类别:
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
APOL1 长期肾移植结果网络 (APOLLO) 临床中心
- 批准号:
9439431 - 财政年份:2017
- 资助金额:
$ 61.63万 - 项目类别:
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
APOL1 长期肾移植结果网络 (APOLLO) 临床中心
- 批准号:
9975831 - 财政年份:2017
- 资助金额:
$ 61.63万 - 项目类别:
FAMILIAL IGA NEPHROPATHY: GENETIC AND FAMILIAL STUDIES
家族性 IGA 肾病:遗传和家族研究
- 批准号:
7603178 - 财政年份:2007
- 资助金额:
$ 61.63万 - 项目类别:
FAMILIAL IGA NEPHROPATHY: GENETIC AND FAMILIAL STUDIES
家族性 IGA 肾病:遗传和家族研究
- 批准号:
7380415 - 财政年份:2006
- 资助金额:
$ 61.63万 - 项目类别:
FAMILIAL IGA NEPHROPATHY: GENETIC AND FAMILIAL STUDIES
家族性 IGA 肾病:遗传和家族研究
- 批准号:
7198544 - 财政年份:2005
- 资助金额:
$ 61.63万 - 项目类别:
Familial IgA nephropathy: genetic and familial studies
家族性 IgA 肾病:遗传和家族研究
- 批准号:
6980515 - 财政年份:2004
- 资助金额:
$ 61.63万 - 项目类别:
COMPARISON OF ENALAPRIL AND LOSARTAN IN POST TRANSPLANT ERYTHROCYTOSIS
依那普利和氯沙坦治疗移植后红细胞增多症的比较
- 批准号:
6244024 - 财政年份:1997
- 资助金额:
$ 61.63万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 61.63万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 61.63万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 61.63万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 61.63万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 61.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 61.63万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 61.63万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 61.63万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 61.63万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 61.63万 - 项目类别:
Miscellaneous Programs